Prestige Consumer Healthcare (PBH) Bets Big On M&A, But Can Clear Eyes Recover?
Prestige Consumer Healthcare (NYSE:PBH) reported Q1 fiscal 2027 sales of $265.7M (+6.5% YoY) and adjusted diluted EPS of $0.98. The company closed Breathe Right (June 12) and LaCorium Health (July 1), adding about $240M annualized revenue and raising FY sales guidance to $1.29B-$1.315B and adjusted EPS to $4.55-$4.65. Clear Eyes faces supply constraints; acquisitions were funded with new debt.
How this was made
The 30-second read
Why it matters
The key trading debate is whether acquisition-driven revenue growth and integration completion can offset near-term margin pressure and higher interest/amortization from new debt, especially with Clear Eyes supply volatility expected into the second quarter.
Market read
Guidance was raised for FY27 sales and adjusted EPS, but the article highlights near-term supply-driven volatility and financing costs that can drive earnings estimate revisions.
What to watch
Transportation cost and product mix drove gross margin down 120 bps; if those persist, acquisition-driven revenue growth may not translate into EPS upside as assumed.
Background
Prestige Consumer Healthcare is integrating two recently closed acquisitions (Breathe Right and LaCorium Health) while managing a legacy Clear Eyes manufacturing constraint.
Ticker impact
Prestige says it closed Breathe Right (June 12) and LaCorium Health (July 1), raising FY27 sales and adjusted EPS guidance while Clear Eyes faces a supply bottleneck.
Choppy trading likely around leverage/interest-cost concerns versus confidence in integration and second-half stabilization.
The article provides concrete deal timing, guidance ranges, and quantified debt/interest/amortization impacts, but it is still an editorial framing rather than a fresh filing or print.
Market effects
Signals continued consolidation in consumer healthcare and that integration execution plus manufacturing throughput are key swing factors for margins.
Limited direct regional read-through; mentions international organic decline tied to distributor timing rather than demand collapse.
Deal adds brands sold in 20+ countries, but the article’s actionable focus is company-specific guidance and leverage.
Counterpoint
The guidance lift may be more debt-financed than organic, and Clear Eyes bottleneck could persist longer than management’s back-half stabilization timeline.
Key entities
- companyPrestige Consumer Healthcare
NYSE-listed consumer healthcare company anchoring its portfolio with Dramamine and Compound W, and integrating Breathe Right and LaCorium Health.
- acquisition_targetBreathe Right
Brand acquired June 12, expected to add about $200 million in annual revenue and launching new Sport strip variants.
- acquisition_targetLaCorium Health
Dermal therapy brand acquired July 1, adding about $40 million in annualized revenue and expanding eczema and cold sore exposure.
- brandClear Eyes
Legacy eye care brand facing a manufacturing bottleneck at the Pillar5 facility, driving near-term sales volatility.
